Healthcare Jan 19, 2022 06:12 PM (GMT+8) · EqualOcean
On the 19th, yiouda health learned that the former Sinopharm capital held the "Jianyi capital 2021 fund Partner Conference and new brand press conference" in Shanghai, and officially announced that the Sinopharm capital brand was upgraded and renamed "Jianyi capital", and the original team worked together to build a pharmaceutical equity investment institution with distinctive characteristics of "CVC + IVC". In 2012, Sinopharm group and the management team jointly initiated the establishment of Sinopharm capital, one of the earliest equity investment institutions focusing on medical health investment in China. Since its establishment, Sinopharm capital has managed a total of 7 funds, with a management fund scale of more than 6.5 billion yuan. It has invested nearly 80 star enterprises including Sinopharm oral cavity, funuojian biology, Chengyi biology, Lingke pharmaceutical, JinFang pharmaceutical, senyi intelligence, saifen technology, aide technology, Juyi science and technology, Xiantong medicine, kangliming biology, etc, Successful harvest of IPOs of Aibo medical, yahuilong, Heyu medicine, Anbo biology, etc. In terms of investment strategy, Jianyi capital has taken the lead in putting forward the investment strategy of "innovation + integration" in the industry. In addition to the in-depth layout at the innovation end, Jianyi capital has also built a solution provider including online and offline integration of the oral industry, pharmaceutical academic promotion enterprises, pharmaceutical retail enterprises, medical intelligent logistics service enterprises, etc. in the form of holding investment. It is reported that Jianyi capital will focus on five fields: new molecular technology, innovative biotherapy, innovative instruments, precision diagnosis and treatment and intelligent medical treatment, and deeply cover cutting-edge technologies with global leading advantages.

This text is a result of machine translation.